<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04715139</url>
  </required_header>
  <id_info>
    <org_study_id>AIRR-0006</org_study_id>
    <nct_id>NCT04715139</nct_id>
  </id_info>
  <brief_title>Evaluate the Continued Safety and Performance of the Foot and Ankle Products</brief_title>
  <official_title>A Multi-Center, Prospective Registry to Evaluate the Continued Safety and Performance of the Foot and Ankle Products</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arthrex, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arthrex, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the registry is to evaluate the continued safety and performance of the&#xD;
      Arthrex ProStop® implant used to treat hyperpronated foot.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To assess safety, related adverse events will be evaluated at six months postoperative and at&#xD;
      one-year postoperative time points. To evaluate performance, physical exam and imaging of the&#xD;
      target area of the body will be evaluated at three months postoperative. Additionally,&#xD;
      patient reported outcomes will be evaluated at three months postoperative, six months&#xD;
      postoperative and one year postoperative using the Visual Analogue Scale (VAS), Veterans Rand&#xD;
      12-Item Health Survey (VR-12) and Foot and Ankle Ability Measures (FAAM).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2024</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>To assess change in Visual Analogue Scale (VAS) survey</measure>
    <time_frame>preoperatively, 3 months, 6 months and 12 months post operative</time_frame>
    <description>Patient reported pain scale 0-10 point scale (0 min, 10 max)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To assess changes in Veterans RAND Health (VR-12) survey</measure>
    <time_frame>preoperatively, 3 months, 6 months and 12 months post operative</time_frame>
    <description>Patient reported changes in general health and mental survey. Average score is 50 (negative answers bring scores down, positive answers bring score up)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To assess changes in Foot and Ankle Ability Measures (FAAM) survey</measure>
    <time_frame>preoperatively, 3 months, 6 months and 12 months post operative</time_frame>
    <description>Patient reported change to physical function for individuals with foot and ankle related impairments. A higher score represents a higher level of physical function</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Hyperpronated Foot</condition>
  <arm_group>
    <arm_group_label>Arthrex ProStop®</arm_group_label>
    <description>The ProStop® arthroereisis subtalar implant is intended to assist in treating the hyperpronated foot by stabilizing the subtalar joint. The main goal is to block forward, downward, medial displacement of the talus, and to help in reducing the talonavicular joint, thereby limiting excessive valgus of the hindfoot.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Arthrex ProStop Implant</intervention_name>
    <description>The ProStop® arthroereisis subtalar implant is intended to assist in treating the hyperpronated foot by stabilizing the subtalar join</description>
    <arm_group_label>Arthrex ProStop®</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Approximately 50 subjects, male and female, age &gt;2 to 17 years of age from the general&#xD;
        population who are scheduled for surgery using the Arthrex ProStop® implant for treatment&#xD;
        of hyperpronated foot. Subjects will be recruited from the surgeon's patient population.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject requires surgery for treatment of hyperpronated foot using the Arthrex&#xD;
             ProStop® implant&#xD;
&#xD;
          2. Age &gt;2 to 17 years&#xD;
&#xD;
          3. Subject is not pregnant, nursing, prisoner, or ward of the state&#xD;
&#xD;
          4. Subject or subject's representative signed informed consent and assent when,&#xD;
             applicable, and is willing and able to comply with all study requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Insufficient quantity or quality of bone.&#xD;
&#xD;
          2. Blood supply limitations and previous infections, which may retard healing.&#xD;
&#xD;
          3. Foreign-body sensitivity.&#xD;
&#xD;
          4. Any active infection or blood supply limitations.&#xD;
&#xD;
          5. Conditions that tend to limit the patient's ability or willingness to restrict&#xD;
             activities or follow directions during the healing period.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Samantha Martino</last_name>
    <phone>800.933.7001</phone>
    <phone_ext>73506</phone_ext>
    <email>samantha.martino@arthrex.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Barrett Podiatry</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monica Guerrero</last_name>
      <phone>210-479-3233</phone>
      <email>mguerrero@barrettpodiatry.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 15, 2021</study_first_submitted>
  <study_first_submitted_qc>January 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 20, 2021</study_first_posted>
  <last_update_submitted>September 3, 2021</last_update_submitted>
  <last_update_submitted_qc>September 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

